Format

Send to

Choose Destination
Eur J Cancer. 2016 Jan;53:125-34. doi: 10.1016/j.ejca.2015.09.013. Epub 2015 Dec 17.

Survival of patients with advanced metastatic melanoma: The impact of novel therapies.

Author information

1
Department of Dermatology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany. Electronic address: selma.ugurel@uk-essen.de.
2
28355 Bremen, Germany.
3
Melanoma, Immunotherapy and Innovative Therapy Unit, Istituto Nazionale Tumori, Fondazione "G. Pascale", Naples, Italy.
4
Massachusetts General Hospital, Boston, MA, USA.
5
Dermatology Department, Timone Hospital and Aix-Marseille University, Marseille, France.
6
University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany.
7
Royal Marsden Hospital NHS Foundation Trust, London, UK.
8
Melanoma Institute Australia and The University of Sydney, Sydney, NSW, Australia.
9
University of Manchester, The Christie NHS Foundation Trust, Manchester, UK.
10
Peter MacCallum Cancer Centre, East Melbourne, VIC, Australia; University of Melbourne, Parkville, VIC, Australia.
11
University of California, Los Angeles, CA, USA.
12
Gustave Roussy Cancer Campus, Villejuif Grand-Paris, France.
13
Department of Dermatology, University Hospital Essen, University Duisburg-Essen, 45122 Essen, Germany.
14
Center for Dermatooncology, Department of Dermatology, University Tuebingen, 72074 Tuebingen, Germany.

Abstract

The survival of advanced metastatic melanoma has been greatly improved within the past few years. New therapeutic strategies like kinase inhibitors for BRAF-mutant melanoma and immune checkpoint blockers proved to prolong survival times within clinical trials, and many of them have already entered routine clinical use. However, these different treatment modalities have not yet been tested against each other, which complicate therapy decisions. We performed an explorative analysis of survival data from recent clinical trials. Thirty-five Kaplan-Meier survival curves from 17 trials were digitised, re-grouped by matching inclusion criteria and treatment line, and averaged by therapy strategy. Notably, the survival curves grouped by therapy strategy revealed a very high concordance, even if different agents were used. The greatest survival improvement was observed with the combination of BRAF plus MEK inhibitors as well as with Programmed-death-1 (PD1) blockers with or without cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blockers, respectively, with these two treatment strategies showing similar survival outcomes. For first-line therapy, averaged survival proportions of patients alive at 12 months were 74.5% with BRAF plus MEK inhibitor treatment versus 71.9% with PD-1 blockade. This explorative comparison shows the kinase inhibitors as similarly effective as immune checkpoint blockers with regard to survival. However, to confirm these first trends for implementation into an individualised treatment of melanoma patients, data from prospective clinical trials comparing the different treatment strategies head-to-head have to be awaited.

KEYWORDS:

Immune checkpoint blockers; Kinase inhibitors; Melanoma; Survival; Therapy

PMID:
26707829
DOI:
10.1016/j.ejca.2015.09.013
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center